Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-12-05
2006-12-05
Kim, Vickie (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S212080, C424S451000, C424S464000
Reexamination Certificate
active
07144880
ABSTRACT:
The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.
REFERENCES:
patent: 3261828 (1966-07-01), Uskokovic et al.
patent: 3384635 (1968-05-01), Calabateas et al.
patent: 3415814 (1968-12-01), Calabateas et al.
patent: 4076823 (1978-02-01), Wade et al.
patent: 4110337 (1978-08-01), Szarvasi
patent: 4495101 (1985-01-01), Klaubert et al.
patent: 4751223 (1988-06-01), Glamkowski et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5041438 (1991-08-01), Hsu
patent: 5288514 (1994-02-01), Ellman
patent: 5324726 (1994-06-01), Bock et al.
patent: 5597915 (1997-01-01), Chambers et al.
patent: 5776946 (1998-07-01), McGeer et al.
patent: 5861380 (1999-01-01), Gyorkos et al.
patent: 6004942 (1999-12-01), Firestein et al.
patent: 6080588 (2000-06-01), Glick
patent: 2001/0016583 (2001-08-01), Glick et al.
patent: 2002/0128208 (2002-09-01), Snyder et al.
patent: 2003/0119029 (2003-06-01), Glick et al.
patent: 0 349 949 (1990-01-01), None
patent: WO 90/05305 (1990-05-01), None
patent: WO 00/19200 (2000-04-01), None
Köhler and Milstein, Nature, 256:495-497 [1975].
Kozbor et al., Immunol. Today, 4:72 [1983].
Huse et al., Science, 246:1275-1281 [1989].
Adachi, M., et al., “Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the Fas Antigen Gene oflprMice,” PNAS. USA- 90:1756-1760 (1993).
Adelman, N.E., et al., Treatment of (NZB X NZW)F1 Disease with Anti-I-A Monoclonal Antibodies; J. Exp. Med., 158:1350-1355 (1983).
Baader, S.L., et al., “Uptake and Cytotoxicity of Ascorbic Acid and Dehydroascorbic Acid in Neuroblastoma (SK-N-SH) and Neuroedodermal (SK-N-LO) Cells,” Anticancer Research-14:221-228 (1994).
Beale, P.J., et al., “BCL-2 Family Protein Expression and Platinum Drug Resistance in Ovarian Carcinoma,” British Journal of Cancer- 82 (2) :436-440 (2000).
Cole et al., in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 [1985].
Boojamra, C.G., et al., “Solid-Phase Synthesis of 1,4-Benzodiazepine-2,5-Diones. Library Preparation and Demonstration of Synthesis Generality,” J. Org . Chem.-62:1240-1256 (1997).
Bunin, BA., et al., “A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodlazepine Derivatives,” J. Am. Chem. Soc. -114:10997-10998 (1992).
Bunin, B.A., et al., “The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Libra ,” PNAS USA-91:4708-4712 (1994).
Chumakov, A.M. “Analysis of p53 Transactivation Through High-Affinity Binding Sites,” Oncogene-8:3005-3011 (1993).
Cohen, P.L., et al., “Lpr and.gld: Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease,” Annu. Rev. Immunol.—9:243-269 (1991).
Crabtree, R.H., “A New Type of Hydrogen Bond,” Science 282:2000-2001 1998.
Desoize, B., “Anticancer Drug Resistance and Inhibition of Apoptosis,” Anicancer Research—14:2291-2294 1994.
Doble, A., et al., “Labelling of Peripheral-Type Benzodiazepine Binding Sites in Human Brain with [3H]11195:Anatomical and Subcellular Distribution,” Brain Research Bulletin,18:49-61 1987.
Donadio, J.V., et al., Immunosuppressive Drug Therapy in Lupus Nephritis, American Journal of Kidney Diseases—21(3):239-250 1993.
Ermak, T.H., et al., “Treatment of Murine Lupus with Monoclonal Antibody to L3T4,” Laboratory Investigation—61(4)447-456 1989.
Gallant, J.E., et al., “Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine,” The Journal of Infectious Diseases—166:1223-1227 1992.
Garcia-Calvo, M., et al. “Inhibition of Human Caspases by Peptide-Based and Macromolecular Inhibitors,” The Journal of Biological Chemistry—273(49):32608-32613 1998.
Gorczyca, W., et al., “Induction of DNA Strand Breaks Associated with Apoptosis During Treatment of Leukemias,” Leukemia—7(5):659-670 1993.
Gordon, C., et al., “Chronic Therapy with Recombinant Tumor Necrosis Factor-α in Autoimmune NZB/NZW Fi Mice,” Clinical Immunology and Immunopatholoy—52:421-434 1989.
Hahn, B.H., et al., “Influence of Cyclophosphamide and Other Immunosuppressive Drugs on Immune Disorders and Neoplasia in NZB/NZW Mice,” Arthritis and Rheumatism—18(2):145-152 1975.
Hang, L., et al., “A Spontaneous Rheumatoid Arthritis-Like Disease in MR/1 Mice,” J. Ex p. Mod. -155:1690-1701 1982.
Horowitz, R.E., et al., “Cyclophosphamide Treatment of Mouse Systemic Lupus Erythematosus,” Laboratory Investigation—21(3):199-206 1969.
Itoh, N., et al., “The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis,” Cell—66:233-243 1991.
Koopman, W.J., et al., “The MRL lpr/lpr Mouse. A Model for the Study of Rheumatoid Arthritis,” Scand. J. Rheumatolo—Suppl 75:284-o289 1988.
Korsmeyer, S.J., “Bel-2 Initiates a New Category of Oncogenes: Regulators of Cell Death,” Blood—80(4):879-886 1992.
Liu, J.R., et al., “Belox, is Expressed in Ovarian Carcinoma and Modulates Chemotherapy-induced Apoptosis,” Gynecologic Oncology—70:398-403 1998.
Los, M., et al., “The Role of Caspases in Development, Immunity, and Apoptotic Signal Transduction: Lessons from Knockout Mice,” Immunity—10:629-639 1999.
Luria, et al., General Viology—3rd edition, 436-446 1978—Eds. John Wile & Sons, New York.
Gordon, E.M., et al., “Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis Library Screening Strategies, and Future Directions,” Journal of Medicinal Chemistry- 37(10):1385-1401 1994.
Marino, M., et al., “Prevention of Systemic Lupus Erythematosus in MRL/Ipr Mice by Administration of an Immunoglobulin-Binding peptide,” Nature Biotechnology—18:735-739 2000.
McDonnell, T.J., et al., “Progession from Lymphoid Hyperplasia to High-Grade Malignant Lymphoma in Mice Transgenic for the t(14;18),” Nature—349:254-256 1991.
Nagata, S., “Human Autoimmune Lymphoproliferative Syndrome, a Defect in the Apoptosis-Inducing Fas Receptor: A Lesson from the Mouse Model,” J. Hum. Genet—43:2-8 1998.
Okuyama, H., et al., “Analysis of Defective Delayed-Type Hypersensitivity in Autoimmune Mice BearingIprGene,” Clin. ,, Ex. p. ImmunoL—63:87-94 1986.
Okuyama, H., et al., “Effect of Cyclophosphamide Pretreatment on Defective Delayed-Type Hypersensitivity in Autoimmune-Prone MRL Mice,” Int Arch. Allergy Appl. Immunol.—88:394-401 (1989).
Ozols, R.F., “Paclitaxel Plus Carboplatin in the Treatment of Ovarian Cancer,” Seminars in Oncology 26(1)(Supp.2 :84-89 (1999).
Pestell, K.E., et al., “Characterization of the P53 Status, BCL-2 Expression and Radiation and Platinum Drug Sensitivity of a Panel of Human Ovarian Cancer Cell Lines,” Int J. Cancer—77:913-918 1998.
Raynaud, F.I., et al., “Intracellular Metabolism of the Orally Active Platinum Drug JM216: Influence of Glutathione Levels,” Br. J. Cancer—74(3) :380-?386 1996.
Russell, J.H., et al., “Mature T Cells of Autoimmunelpr/lprMice have a Defect in Antigen-Stimulated Suicide,” Proc. Nat. Acad. Sci. USA—90:4409-4413 1993.
Sakata, K., et al., “Role of Fas/FasL Interaction in Physiology and Pathology: The Good and the Bad,” Clinical Immunology and Immunopa
Kim Vickie
Medlen & Carroll LLP
Regents of the University of Michigan
LandOfFree
Compositions relating to novel compounds and targets thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions relating to novel compounds and targets thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions relating to novel compounds and targets thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3684571